BioFlorida Masthead
JOIN BIOFLORIDA      MEMBERS ONLY      CALENDAR OF EVENTS      NEWS      CONTACT US
  Interior Arrows
NEWS

 

Join our LinkedIn groupFollow us on TwitterBecome a Fan on Facebook

 

blue gradient
Thursday, August 19, 2010
SPEID & ASSOCIATES TO HOST SESSION ON DRUG DEVELOPMENT AT BIOFLORIDA OCTOBER 2010

  FOR IMMEDIATE RELEASE
 
SPEID & ASSOCIATES TO HOST SESSION ON DRUG DEVELOPMENT AT BIOFLORIDA OCTOBER 2010

SAN DIEGO, Calif. (August 19, 2010) – Speid & Associates, an international regulatory affairs and drug development consultancy today announced that Dr. Speid, President of the Company will be chairing a session on The Ten Mistakes that Senior Management Teams Make With Investigational New Drugs and Clinical Trial Applications at BioFlorida’s 13th Annual Conference (October 24 – 26, 2010). This session will emphasize the importance of companies following a logical pathway to gaining an understanding of a drug’s safety and efficacy profile. The session will include an interactive workshop as well as a presentation, and question and answer session.

Dr. Speid is a recognized global regulatory affairs expert. She is the author of a book on clinical trials published by Oxford University Press which is written for the lay person. The book Clinical Trials What Patients and Healthy Volunteers Need to Know is now in bookstores.  

“Dr. Speid’s session on drug development and the importance of clinical trials adds to the impressive roster of workshops, exhibits and events at BioFlorida’s Annual Conference. It will give conference attendees working in biotech and those interested in – or connected to the field – important insights to help them bring drugs successfully to the market,” said Russell Allen, President and CEO of BioFlorida, Inc., the statewide association focused on advancing Florida’s bioscience industry.

# # #

About Speid & Associates, Inc.
Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in San Diego, California. Speid & Associates assists life science companies move new chemical entities to the finish line expeditiously by developing effective global regulatory strategies for the international pharmaceutical and biotechnology industries. 
Lorna Speid, BPharm, MRPharmS, PhD, RAC, is the president of Speid and Associates, Inc., a regulatory affairs and drug development consultancy. Dr. Speid has worked for the international pharmaceutical industry since the late 1980s. In addition to her work as a consultant, her earlier research and clinical trial experience in the pharmaceutical industry has given her invaluable insight into the issues faced by patients and healthy volunteers who take part in, or are considering taking part in, clinical trials. She lives in San Diego. For more information visit: www.drugstomarket.com

About BioFlorida
BioFlorida is the voice of Florida’s bioscience industry association, and represents more than 200 member companies and research organizations in the biotechnology, pharmaceutical and medical device fields. Operating as a not-for-profit organization, BioFlorida works to facilitate and advance innovations in the healthcare, agriculture and energy sectors for its membership base. BioFlorida members are involved in biomedical research and development, medical device manufacturing, clinics and hospitals, academia, government and non-profit organizations, and industry services/products. BioFlorida’s leadership and programs positively influence the growth of the industry through networking and initiatives related to capital formation, advocacy, workforce development, education and commercialization of research. This year, the BioFlorida Institute was established to provide support for K-12 science education, workforce development programs as well as professional development. For more information, visit www.bioflorida.com.

Contact Speid & Associates, Inc.
Lorna Speid, PhD
President
858-793-1295
lspeid@sndtm.com

Contact for BioFlorida
Luis F. Perez
Carey O’Donnell PR Group
561-832-3231 x13

  

  
Back  Email this Press Release Print View All Press Releases